Clinical Research Directory

Phase A: contextual analysis Inclusion Criteria: * Community pharmacists and technicians of 5 participating pharmacies in the French-speaking part of Switzerland and 5 in the German-speaking part of Switzerland * Primary care physicians working in collaboration or in the neighbourhood of the participating pharmacies * Patients with long-term treatments, who are a regular patients of the included pharmacies * International research groups who have implemented NMS within their countries or similar interventions. Exclusion Criteria: * Patients not willing to participate * Patients that do not speak French or German Phase B: hybrid type 2 effectiveness-implementation study Patients are eligible for the myCare Start-I phase B study if : * They are taking part in the myCare Start service * They have been newly prescribed one or more new long-term medications in accordance with one of the five defined long-term conditions (cardiovascular disease (incl. hypertension and thromboprophylaxis), diabetes, hyperlipidaemia, depression and respiratory illness (asthma, COPD)) * They are 18 years or older * They have mandatory basic health insurance in Switzerland * They are able to self-manage treatment (i.e. they live at home without any support to manage their medication, exception: patient uses a pill dispenser and fills it in by him-/herself). * They understand language spoken by pharmacy staff and are able to read and understand study documents (ge, fr) * They are able to understand and willing to consent to the myCare Start study (including the agreement on self-reported questionnaires and collection of health care data via their health insurance company) Exclusion criteria: • Patients participating or having participated in an education program about their disease or treatment in the last 3 months, led by healthcare providers such as physicians, nurses, pharmacists or other (e.g. education provided by nurses for type I diabetes patients). myCare Start definition of a new medication: A new medication is a medication that has not been previously dispensed to the patient. This includes one or more new medications for a new diagnosis and or new medications for pre-existing diagnosis of a long-term condition. Operational definition of a new medication: * Active ingredient is indicated for one of the five long-term conditions (cardiovascular disease (incl. hypertension and thromboprophylaxis), diabetes, hyperlipidaemia, depression and respiratory illness (asthma, COPD)). * Patient has never had this active ingredient dispensed before or restarts an active ingredient after a period of interruption of at least 12 months. The new active ingredient can be part of a combo preparation (e.g. a diuretic added to an ACE inhibitor into the same preparation) * Patient has had no change in active ingredient but has an important change in treatment administration, such as: * Change of galenic form (e.g. two different types on inhalators for asthma/COPD) * Intensification of dosage regimen (e.g. twice a day instead of once a day) * The following change is not considered as medication initiation: * New dosage of already known active ingredient (e.g. dose escalation of antidepressants) * Simplification of administration mode (e.g. metformin 1000mg 1-0-0 instead of 500mg 1-0-1; change in antihypertensive drug regimen in elderly patients having vertigo in the morning: 0-0-X instead of X-0-0)